| The cancer cell secretome: a good source for discovering biomarkers? MP Pavlou, EP Diamandis Journal of proteomics 73 (10), 1896-1906, 2010 | 250 | 2010 |
| Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer V Kulasingam, MP Pavlou, EP Diamandis Nature Reviews Cancer 10 (5), 371-378, 2010 | 192 | 2010 |
| The long journey of cancer biomarkers from the bench to the clinic MP Pavlou, EP Diamandis, IM Blasutig Clinical chemistry 59 (1), 147-157, 2013 | 185 | 2013 |
| Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology GS Karagiannis, MP Pavlou, EP Diamandis Molecular oncology 4 (6), 496-510, 2010 | 183 | 2010 |
| Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay AP Drabovich, MP Pavlou, A Dimitromanolakis, EP Diamandis Molecular & Cellular Proteomics 11 (8), 422-434, 2012 | 96 | 2012 |
| Phage resistance at the cost of virulence: Listeria monocytogenes serovar 4b requires galactosylated teichoic acids for InlB-mediated invasion ET Sumrall, Y Shen, AP Keller, J Rismondo, M Pavlou, MR Eugster, ... PLoS pathogens 15 (10), e1008032, 2019 | 85 | 2019 |
| MassIVE. quant: a community resource of quantitative mass spectrometry–based proteomics datasets M Choi, J Carver, C Chiva, M Tzouros, T Huang, TH Tsai, B Pullman, ... Nature methods 17 (10), 981-984, 2020 | 65 | 2020 |
| Nipple aspirate fluid proteome of healthy females and patients with breast cancer MP Pavlou, V Kulasingam, ER Sauter, B Kliethermes, EP Diamandis Clinical chemistry 56 (5), 848-855, 2010 | 55 | 2010 |
| Proteomic and mass spectrometry technologies for biomarker discovery AP Drabovich, MP Pavlou, I Batruch, EP Diamandis Proteomic and metabolomic approaches to biomarker discovery, 17-37, 2013 | 44 | 2013 |
| Dynamics of protein expression reveals primary targets and secondary messengers of estrogen receptor alpha signaling in MCF-7 breast cancer cells AP Drabovich, MP Pavlou, C Schiza, EP Diamandis Molecular & Cellular Proteomics 15 (6), 2093-2107, 2016 | 37 | 2016 |
| Coupling proteomics and transcriptomics in the quest of subtype‐specific proteins in breast cancer MP Pavlou, A Dimitromanolakis, EP Diamandis Proteomics 13 (7), 1083-1095, 2013 | 32 | 2013 |
| Integrating meta-analysis of microarray data and targeted proteomics for biomarker identification: application in breast cancer MP Pavlou, A Dimitromanolakis, E Martinez-Morillo, M Smid, JA Foekens, ... Journal of proteome research 13 (6), 2897-2909, 2014 | 30 | 2014 |
| In-depth proteomic delineation of the colorectal cancer exoproteome: Mechanistic insight and identification of potential biomarkers GS Karagiannis, MP Pavlou, P Saraon, N Musrap, A Xie, I Batruch, ... Journal of proteomics 103, 121-136, 2014 | 29 | 2014 |
| The search for new prostate cancer biomarkers continues M Pavlou, EP Diamandis Clinical Chemistry 55 (7), 1277-1279, 2009 | 28 | 2009 |
| Proteomic and metabolomic approaches to biomarker discovery AP Drabovich, MP Pavlou, I Batruch, EP Diamandis, HJ Issaq, ... Academic Press, Frederick, MD, 2013 | 16 | 2013 |
| A Proteogenomic Resource Enabling Integrated Analysis of Listeria Genotype–Proteotype–Phenotype Relationships AR Varadarajan, S Goetze, MP Pavlou, V Grosboillot, Y Shen, ... Journal of proteome research 19 (4), 1647-1662, 2020 | 11 | 2020 |
| The athletes of science M Pavlou, EP Diamandis Nature 478 (7369), 419-419, 2011 | 9 | 2011 |
| Cardiac targeting peptide: From identification to validation to mechanism of transduction KS Feldman, MP Pavlou, M Zahid Bio-Carrier Vectors: Methods and Protocols, 97-112, 2021 | 6 | 2021 |
| Validation of candidate protein biomarkers MP Pavlou, EP Diamandis Genomic and personalized medicine 1 (2), 263-70, 2012 | 4 | 2012 |
| Validation of extracellular ligand–receptor interactions by Flow-TriCEPS LA Lopez-Garcia, L Demiray, S Ruch-Marder, AK Hopp, MO Hottiger, ... BMC research notes 11, 1-7, 2018 | 3 | 2018 |
